Document Detail


Predictors of immunomodulator use as early therapy in pediatric Crohn's disease.
MedLine Citation:
PMID:  16394876     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
GOALS: The goals of this study were to identify markers in a patient's presentation and disease progression that predict the need for the use of immunomodulators in a pediatric population. BACKGROUND: Although immunomodulator safety and efficacy have been documented in Crohn's disease, models for predicting outcome and the need for immunomodulators (azathioprine, 6-mercaptopurine, or methotrexate) early in the disease course have not been investigated in children or adults. METHODS: Data on newly diagnosed Crohn's disease patients were prospectively collected within 3 weeks of diagnosis, 6 months after diagnosis, and 1 year after diagnosis. Information collected at each visit included medication use and disease activity assessment. RESULTS: A total of 57 patients who were followed for > or = 6 months were evaluated. Overall, 34 of 57 (59.6%) were started on immunomodulators within 1 year of diagnosis. Mean serum albumin (3.35 g/dL vs. 3.7 g/dL, P = 0.013) and hematocrit (33.3% vs. 35.9%, P = 0.023) at diagnosis were lower, and erythrocyte sedimentation rate (32 vs. 12, P = 0.011) at diagnosis was higher in patients who required immunomodulators. The total Pediatric Crohn's Disease Activity Index score as well as the physical examination score and patient recall score within the PCDAI at diagnosis were not different among those who received immunomodulators and those that did not. CONCLUSIONS: Immunomodulators are frequently used within 1 year of diagnosis in pediatric Crohn's disease. Lower serum albumin levels and hematocrit, and elevated erythrocyte sedimentation rate at diagnosis may predict the need for immunomodulators earlier in the disease course.
Authors:
Douglas A Jacobstein; Petar Mamula; Jonathan E Markowitz; Mary Leonard; Robert N Baldassano
Related Documents :
17038626 - Tlrs in the gut. iii. immune responses to flagellin in crohn's disease: good, bad, or i...
8902486 - Acute respiratory failure due to tracheobronchial involvement in crohn's disease.
11444476 - Bone density reduction in patients with crohn disease and associations with demographic...
1620816 - The diagnosis of intra-abdominal abscesses in patients with severe crohn's disease.
8776026 - Diagnosis and management of tyrosinemia type i.
15472486 - A case of shaker dog disease in a miniature dachshund.
Publication Detail:
Type:  Journal Article    
Journal Detail:
Title:  Journal of clinical gastroenterology     Volume:  40     ISSN:  0192-0790     ISO Abbreviation:  J. Clin. Gastroenterol.     Publication Date:  2006 Feb 
Date Detail:
Created Date:  2006-01-05     Completed Date:  2006-04-20     Revised Date:  -    
Medline Journal Info:
Nlm Unique ID:  7910017     Medline TA:  J Clin Gastroenterol     Country:  United States    
Other Details:
Languages:  eng     Pagination:  145-8     Citation Subset:  IM    
Affiliation:
Division of Gastroenterology and Nutrition, Children's Hospital of Philadelphia, Philadelphia, PA 19104, USA.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
6-Mercaptopurine / therapeutic use*
Adolescent
Azathioprine / therapeutic use*
Biological Markers / blood*
Chi-Square Distribution
Child
Child, Preschool
Crohn Disease / blood*,  drug therapy*
Disease Progression
Female
Humans
Immunosuppressive Agents / therapeutic use*
Male
Methotrexate / therapeutic use*
Predictive Value of Tests
Prospective Studies
Statistics, Nonparametric
Chemical
Reg. No./Substance:
0/Biological Markers; 0/Immunosuppressive Agents; 446-86-6/Azathioprine; 50-44-2/6-Mercaptopurine; 59-05-2/Methotrexate
Comments/Corrections
Comment In:
J Clin Gastroenterol. 2006 Feb;40(2):93-5   [PMID:  16394867 ]

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Clinical utility of wireless capsule endoscopy: experience with 200 cases.
Next Document:  The role of antibiotic prophylaxis in the treatment of acute pancreatitis.